192 related articles for article (PubMed ID: 37453852)
1. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D; Fabara S; Loseke I; Alok A; Al-Ani H; Bazikian Y
Heart Lung Circ; 2023 Sep; 32(9):1049-1056. PubMed ID: 37453852
[TBL] [Abstract][Full Text] [Related]
2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
[TBL] [Abstract][Full Text] [Related]
4. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.
Vyas R; Panchal V; Jain S; Sondhi M; Singh M; Jaisingh K; Thotamgari SR; Thakre A; Modi K
PLoS One; 2024; 19(4):e0301704. PubMed ID: 38635724
[TBL] [Abstract][Full Text] [Related]
6. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
[TBL] [Abstract][Full Text] [Related]
7. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
[TBL] [Abstract][Full Text] [Related]
8. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
[TBL] [Abstract][Full Text] [Related]
9. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
[TBL] [Abstract][Full Text] [Related]
10. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY; Owens A; Geske JB; Wolski K; Naidu SS; Smedira NG; Cremer PC; Schaff H; McErlean E; Sewell C; Li W; Sterling L; Lampl K; Edelberg JM; Sehnert AJ; Nissen SE
J Am Coll Cardiol; 2022 Jul; 80(2):95-108. PubMed ID: 35798455
[TBL] [Abstract][Full Text] [Related]
11. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
[TBL] [Abstract][Full Text] [Related]
12. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
Heitner SB; Jacoby D; Lester SJ; Owens A; Wang A; Zhang D; Lambing J; Lee J; Semigran M; Sehnert AJ
Ann Intern Med; 2019 Jun; 170(11):741-748. PubMed ID: 31035291
[TBL] [Abstract][Full Text] [Related]
13. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of mavacamten in patients with hypertrophic cardiomyopathy.
Liao HL; Liang Y; Liang B
J Cardiovasc Med (Hagerstown); 2024 Jul; 25(7):491-498. PubMed ID: 38814051
[TBL] [Abstract][Full Text] [Related]
15. Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Marar R; Geske JB; Gersh BJ; Anavekar NS
Curr Probl Cardiol; 2023 Jan; 48(1):101429. PubMed ID: 36167226
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
[TBL] [Abstract][Full Text] [Related]
17. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
[TBL] [Abstract][Full Text] [Related]
18. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
[TBL] [Abstract][Full Text] [Related]
19. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
[TBL] [Abstract][Full Text] [Related]
20. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]